GLP-1 Receptor Activation Modulates Appetite- and Reward-Related Brain Areas in Humans
The DOI matches its Crossref record; 54 of the 56 references it cites were found in a registry or an index.
Abstract
Gut-derived hormones, such as GLP-1, have been proposed to relay information to the brain to regulate appetite. GLP-1 receptor agonists, currently used for the treatment of type 2 diabetes (T2DM), improve glycemic control and stimulate satiety, leading to decreases in food intake and body weight. We hypothesized that food intake reduction after GLP-1 receptor activation is mediated through appetite- and reward-related brain areas. Obese T2DM patients and normoglycemic obese and lean individuals (n = 48) were studied in a randomized, crossover, placebo-controlled trial. Using functional MRI, we determined the acute effects of intravenous administration of the GLP-1 receptor agonist exenatide, with or without prior GLP-1 receptor blockade using exendin 9-39, on brain responses to food pictures during a somatostatin pancreatic-pituitary clamp. Obese T2DM patients and normoglycemic obese versus lean subjects showed increased brain responses to food pictures in appetite- and reward-related brain regions (insula and amygdala). Exenatide versus placebo decreased food intake and food-related brain responses in T2DM patients and obese subjects (in insula, amygdala, putamen, and orbitofrontal cortex). These effects were largely blocked by prior GLP-1 receptor blockade using exendin 9-39. Our findings provide novel insights into the mechanisms by which GLP-1 regulates food intake and how GLP-1 receptor agonists cause weight loss.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“GLP-1 reduces appetite and food intake through its actions in the CNS.212,260,261”
From Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024) · cites this paper as [212]
In the citing paper
“GLP-1RAs work via numerous mechanisms that contribute to weight loss, one of the most well-known of which is the gut-brain axis.212,213,390”
From Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024) · cites this paper as [212]
In the citing paper
“Incretin therapies work in the appetite and reward circuitries to modulate food intake and energy balance, reducing uncontrollable hunger, overeating, and bulimic symptoms (413), although mechanisms are not completely understood.”
From 5. Facilitating Positive Health Behaviors and Well-being to Improve Health Outcomes:Standards of Care in Diabetes—2023 (2023) · cites this paper as [413]
Citations
Cites
IDF Diabetes Atlas: Global estimates for the prevalence of diabetes for 2015 and 2040
Ogurtsova, K., da Rocha Fernandes, J. D., Huang, Y., Linnenkamp, U., Guariguata, L., Cho, N. H., Cavan, D., Shaw, J. E., & Makaroff, L. E. (2017) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2017.03.024 · Cited by 6,966
Prevalence of Obesity and Trends in the Distribution of Body Mass Index Among US Adults, 1999-2010
Flegal, K. M., Carroll, M. D., Kit, B. K., & Ogden, C. L. (2012) · JAMA · doi:10.1001/jama.2012.39 · Cited by 5,385 · cited 1×
“The global rise in obesity and type 2 diabetes (T2DM) prevalence is a major public health problem (1,2).”
BackgroundIDF Diabetes Atlas: Global estimates of the prevalence of diabetes for 2011 and 2030
Whiting, D. R., Guariguata, L., Weil, C., & Shaw, J. (2011) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2011.10.029 · Cited by 3,994
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896 · cited 1×
“GLP-1 stimulates meal-related insulin secretion, inhibits glucagon release, and delays gastric emptying, mechanisms that all contribute to its glucometabolic effects (11).”
BackgroundDeFronzo, R. A., Ratner, R. E., Han, J., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1092 · Cited by 1,559 · cited 1×
“The weight reduction seen during GLP-1 receptor agonist treatment is also observed in the absence of nausea (47).”
BackgroundGlucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.
Flint, A., Raben, A., Astrup, A., & Holst, J. J. (1998) · Journal of Clinical Investigation · doi:10.1172/jci990 · Cited by 1,402 · cited 1×
“In contrast to previous studies (50), we found no statistically significant effects of GLP-1 receptor activation on scores of hunger, fullness, appetite, prospective food consumption, and desire to eat.”
ResultBaxter, M. G., & Murray, E. A. (2002) · Nature Reviews Neuroscience · doi:10.1038/nrn875 · Cited by 1,200 · cited 1×
“The amygdala plays a pivotal role in emotional learning and in the association of cues with reward (33) by encoding the value of the reward predicted by the conditioned stimuli (34).”
BackgroundChanges in brain activity related to eating chocolate: From pleasure to aversion
Small, D. M. (2001) · Brain · doi:10.1093/brain/124.9.1720 · Cited by 1,179 · cited 4×
“The insula is involved in the processing of food-cues and craving for food (31) and has been implicated in the devaluation of food-cues when eating to satiety (32).”
BackgroundInfluentialDrucker, D. J., Buse, J. B., Taylor, K., Kendall, D. M., Trautmann, M., Zhuang, D., & Porter, L. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61206-4 · Cited by 1,070 · cited 3×
“A meta-analysis of the effect of glucagon-like peptide-1 (7-36) amide on ad libitum energy intake in humans.”
BackgroundMethodVilsboll, T., Christensen, M., Junker, A. E., Knop, F. K., & Gluud, L. L. (2012) · BMJ · doi:10.1136/bmj.d7771 · Cited by 970 · cited 6×
“Interestingly, GLP-1-receptor agonists have shown modest but consistent weight loss in humans (14).”
BackgroundResultInfluential
Research works printed but not linked: 1
- Wald, 1990, The shortened version of the Dutch translation of the Profile of Mood States (POMS), Ned Tijdschr Psychol, 45, 86
Cited by
The role of short-chain fatty acids in microbiota–gut–brain communication
Dalile, B., Van Oudenhove, L., Vervliet, B., & Verbeke, K. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0157-3 · Cited by 3,357
Glucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868
GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art
Nauck, M. A., Quast, D. R., Wefers, J., & Meier, J. J. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101102 · Cited by 1,647
Glucagon-like peptide-1 receptor: mechanisms and advances in therapy
Zheng, Z., Zong, Y., Ma, Y., Tian, Y., Pang, Y., Zhang, C., & Gao, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01931-z · Cited by 1,036
Semaglutide lowers body weight in rodents via distributed neural pathways.
Gabery, S., Salinas, C. G., Paulsen, S. J., Ahnfelt-Rønne, J., Alanentalo, T., Baquero, A. F., Buckley, S. T., Farkas, E., Fekete, C., Frederiksen, K. S., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.133429 · Cited by 717
Short chain fatty acids: Microbial metabolites for gut-brain axis signalling
O'Riordan, K. J., Collins, M. K., Moloney, G. M., Knox, E. G., Aburto, M. R., Fülling, C., Morley, S. J., Clarke, G., Schellekens, H., & Cryan, J. F. (2022) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2022.111572 · Cited by 713
Blundell, J., Finlayson, G., Axelsen, M., Flint, A., Gibbons, C., Kvist, T., & Hjerpsted, J. B. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12932 · Cited by 693
“GLP-1 receptors in the human brain helps to regulate appetite and food reward.(11) Animal studies have shown that a GLP-1RA, liraglutide, can access specific areas of the brain involved in appetite regulation.”
BackgroundBrain Insulin Resistance at the Crossroads of Metabolic and Cognitive Disorders in Humans
Kullmann, S., Heni, M., Hallschmid, M., Fritsche, A., Preissl, H., & Häring, H.-U. (2016) · Physiological Reviews · doi:10.1152/physrev.00032.2015 · Cited by 622
“Interestingly, these effects could be blocked by exenidin 9–39, a pharmacological GLP-1 receptor antagonist (367).”
BackgroundSteinert, R. E., Feinle-Bisset, C., Asarian, L., Horowitz, M., Beglinger, C., & Geary, N. (2017) · Physiological Reviews · doi:10.1152/physrev.00031.2014 · Cited by 578
GLP-1 physiology informs the pharmacotherapy of obesity
Drucker, D. J. (2022) · Molecular Metabolism · doi:10.1016/j.molmet.2021.101351 · Cited by 510
Pharmacotherapy of obesity: an update on the available medications and drugs under investigation
Chakhtoura, M., Haber, R., Ghezzawi, M., Rhayem, C., Tcheroyan, R., & Mantzoros, C. S. (2023) · eClinicalMedicine · doi:10.1016/j.eclinm.2023.101882 · Cited by 462
GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes
Muskiet, M. H. A., Tonneijck, L., Smits, M. M., van Baar, M. J. B., Kramer, M. H. H., Hoorn, E. J., Joles, J. A., & van Raalte, D. H. (2017) · Nature Reviews Nephrology · doi:10.1038/nrneph.2017.123 · Cited by 407
Health Benefits of Lactic Acid Bacteria (LAB) Fermentates
Mathur, H., Beresford, T. P., & Cotter, P. D. (2020) · Nutrients · doi:10.3390/nu12061679 · Cited by 393
ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Hilliard, M. E., Isaacs, D., Johnson, E. L., et al. (2023) · Diabetes Care · doi:10.2337/dc23-s005 · Cited by 362
An overview of fermentation in the food industry - looking back from a new perspective
Siddiqui, S. A., Erol, Z., Rugji, J., Taşçı, F., Kahraman, H. A., Toppi, V., Musa, L., Di Giacinto, G., Bahmid, N. A., Mehdizadeh, M., et al. (2023) · Bioresources and Bioprocessing · doi:10.1186/s40643-023-00702-y · Cited by 311
“…β -galactosidases enzyme (Saqib et al. 2017), regulates food intake and prevents weight loss using glucagon-like peptide-1 (GLP-1) (Cho et al. 2014; van Bloemendaal et al. 2014), the anti-inflammatory activity of paraprobiotic CP2305 ( Lactobacillus gas-seri CP2305) by affecting the growth of…”
BackgroundAmerican Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Echouffo-Tcheugui, J. B., Eichorst, B., et al. (2025) · Diabetes Care · doi:10.2337/dc25-s005 · Cited by 305
Pleiotropic Effects of GLP-1 and Analogs on Cell Signaling, Metabolism, and Function
Rowlands, J., Heng, J., Newsholme, P., & Carlessi, R. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00672 · Cited by 302
Farr, O. M., Sofopoulos, M., Tsoukas, M. A., Dincer, F., Thakkar, B., Sahin-Efe, A., Filippaios, A., Bowers, J., Srnka, A., Gavrieli, A., et al. (2016) · Diabetologia · doi:10.1007/s00125-016-3874-y · Cited by 287
“Although amylase showed no changes, lipase increased with liraglutide (F[15] = 12.”
InfluentialAmerican Diabetes Association Professional Practice Committee, ElSayed, N. A., Aleppo, G., Bannuru, R. R., Beverly, E. A., Bruemmer, D., Collins, B. S., Darville, A., Ekhlaspour, L., Hassanein, M., et al. (2024) · Diabetes Care · doi:10.2337/dc24-s005 · Cited by 285
Feeding gut microbes to nourish the brain: unravelling the diet–microbiota–gut–brain axis
Schneider, E., O’Riordan, K. J., Clarke, G., & Cryan, J. F. (2024) · Nature Metabolism · doi:10.1038/s42255-024-01108-6 · Cited by 272
“The delicate balance of GLP-1 and PYY secretion, crucial for controlling food intake, body weight and metabolism, is disrupted in individuals with obesity 208 .”
Bajaj, M. S., McCoy, R. G., Balapattabi, K., Bannuru, R. R., Bellini, N. J., Bennett, A. K., Beverly, E. A., Early, K. B., ChallaSivaKanaka, S., Echouffo-Tcheugui, J. B., et al. (2025) · Diabetes Care · doi:10.2337/dc26-s005 · Cited by 265
Glucagon-like peptide-1 receptors in the brain: controlling food intake and body weight
Baggio, L. L., & Drucker, D. J. (2014) · Journal of Clinical Investigation · doi:10.1172/jci78371 · Cited by 245
“Although the effects of GLP-1R agonists on complex human behaviors linked to reduction in food intake are likely more complex and involve multiple brain regions important for food selection, reward, and appetite (19, 20), 1).”
The impact of gut hormones on the neural circuit of appetite and satiety: A systematic review
Zanchi, D., Depoorter, A., Egloff, L., Haller, S., Mählmann, L., Lang, U. E., Drewe, J., Beglinger, C., Schmidt, A., & Borgwardt, S. (2017) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2017.06.013 · Cited by 242
“…24 studies subjects consumed standardised meals (containing for instance: fibres, soy or chocolate milkshake) with different amounts of protein (van Bloemendaal et al., 2014; Douglas et al., 2015; Gautier et al., 2000; Goldstone et al., 2014; Grosshans et al., 2012; Jastreboff et al., 2016; Karra…”
InfluentialBrown, E., Wilding, J. P. H., Barber, T. M., Alam, U., & Cuthbertson, D. J. (2019) · Obesity Reviews · doi:10.1111/obr.12841 · Cited by 222
Food addiction: a valid concept?
Fletcher, P. C., & Kenny, P. J. (2018) · Neuropsychopharmacology · doi:10.1038/s41386-018-0203-9 · Cited by 221
Regulation of energy balance by a gut–brain axis and involvement of the gut microbiota
Bauer, P. V., Hamr, S. C., & Duca, F. A. (2016) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-015-2083-z · Cited by 216
“For example, gut peptide mimetic drugs have proved successful in both rodents [212, 213], as well as clinically [214, 215] in reducing food intake and obesity.”
BackgroundByrne, C. S., Chambers, E. S., Alhabeeb, H., Chhina, N., Morrison, D. J., Preston, T., Tedford, C., Fitzpatrick, J., Irani, C., Busza, A., et al. (2016) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.115.126706 · Cited by 201
“The exogenous administration of GLP-1 or its analogs and/or PYY reduces brain reward system responses to viewing food pictures in humans (4, 14).”
BackgroundHeppner, K. M., Kirigiti, M., Secher, A., Paulsen, S. J., Buckingham, R., Pyke, C., Knudsen, L. B., Vrang, N., & Grove, K. L. (2015) · Endocrinology · doi:10.1210/en.2014-1675 · Cited by 196
Gasbjerg, L. S., Helsted, M. M., Hartmann, B., Jensen, M. H., Gabe, M. B. N., Sparre-Ulrich, A. H., Veedfald, S., Stensen, S., Lanng, A. R., Bergmann, N. C., et al. (2019) · Diabetes · doi:10.2337/db18-1123 · Cited by 193
“In this study, we assessed the individual and combined contributions of endogenous GIP and GLP-1 to the postprandial changes in glucose and glucoregulatory hormones using the novel GIP receptor antagonist GIP(3-30)NH2 and the well-established GLP-1 receptor antagonist exendin(9-39)NH2.”
BackgroundMethodInfluentialCombination therapy with GLP ‐1 receptor agonist and SGLT2 inhibitor
DeFronzo, R. A. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12982 · Cited by 192
Glucagon-like Peptide-1 and the Central/Peripheral Nervous System: Crosstalk in Diabetes
Muscogiuri, G., DeFronzo, R. A., Gastaldelli, A., & Holst, J. J. (2017) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2016.10.001 · Cited by 171
Liraglutide and obesity: a review of the data so far
Ladenheim, E. (2015) · Drug Design, Development and Therapy · doi:10.2147/dddt.s58459 · Cited by 146
Mansur, R. B., Ahmed, J., Cha, D. S., Woldeyohannes, H. O., Subramaniapillai, M., Lovshin, J., Lee, J. G., Lee, J.-H., Brietzke, E., Reininghaus, E. Z., et al. (2017) · Journal of Affective Disorders · doi:10.1016/j.jad.2016.09.056 · Cited by 164
Eren-Yazicioglu, C. Y., Yigit, A., Dogruoz, R. E., & Yapici-Eser, H. (2021) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2020.614884 · Cited by 127
“…activation of the bilateral insula, left putamen, and right OFC to both food and high-calorie food vs. non-food pictures in T2DM patients and of the right insula and left OFC to high-calorie vs. non-food pictures in obese patients along with reduced food intake (van Bloemendaal et al., 2014).”
BackgroundGLP-1 receptor agonist promotes brown remodelling in mouse white adipose tissue through SIRT1
Xu, F., Lin, B., Zheng, X., Chen, Z., Cao, H., Xu, H., Liang, H., & Weng, J. (2016) · Diabetologia · doi:10.1007/s00125-016-3896-5 · Cited by 157
Microbiota‐gut‐brain axis as a regulator of reward processes
García‐Cabrerizo, R., Carbia, C., O´Riordan, K. J., Schellekens, H., & Cryan, J. F. (2021) · Journal of Neurochemistry · doi:10.1111/jnc.15284 · Cited by 144
“…been described in central brain regions such as hypothalamus and nucleus tractus solitarii (NTS), indicating that these peptides might modulate their responses acting directly in the brain (Ballaz, 2017; Dourish et al., 1989; Göke et al., 1995; Ohkubo et al., 1990; van Bloemendaal et al., 2014).”
BackgroundHomeostatic and non-homeostatic controls of feeding behavior: Distinct vs. common neural systems
Liu, C. M., & Kanoski, S. E. (2018) · Physiology & Behavior · doi:10.1016/j.physbeh.2018.02.011 · Cited by 130
Gulak, M. A., & Murphy, P. (2023) · Canadian Journal of Anesthesia/Journal canadien d'anesthésie · doi:10.1007/s12630-023-02521-3 · Cited by 153
Gault, V. A., Lennox, R., & Flatt, P. R. (2015) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12432 · Cited by 141
van Bloemendaal, L., Veltman, D. J., ten Kulve, J. S., Groot, P. F. C., Ruhé, H. G., Barkhof, F., Sloan, J. H., Diamant, M., & Ijzerman, R. G. (2015) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12506 · Cited by 151
“Comparable MRI acquisition and analyses were used as described previously [16].”
BackgroundMethodSelf-citationDevoto, F., Zapparoli, L., Bonandrini, R., Berlingeri, M., Ferrulli, A., Luzi, L., Banfi, G., & Paulesu, E. (2018) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2018.07.017 · Cited by 140
Nutritional modulation of endogenous glucagon-like peptide-1 secretion: a review
Bodnaruc, A. M., Prud’homme, D., Blanchet, R., & Giroux, I. (2016) · Nutrition & Metabolism · doi:10.1186/s12986-016-0153-3 · Cited by 139
Campos, A., Port, J. D., & Acosta, A. J. (2022) · Brain Sciences · doi:10.3390/brainsci12040431 · Cited by 139
Liu, Y., Ruan, B., Jiang, H., Le, S., Liu, Y., Ao, X., Huang, Y., Shi, X., Xue, R., Fu, X., et al. (2023) · The American Journal of Clinical Nutrition · doi:10.1016/j.ajcnut.2023.04.017 · Cited by 110
He, Z., Gao, Y., Lieu, L., Afrin, S., Cao, J., Michael, N. J., Dong, Y., Sun, J., Guo, H., & Williams, K. W. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.07.008 · Cited by 128
Kabahizi, A., Wallace, B., Lieu, L., Chau, D., Dong, Y., Hwang, E., & Williams, K. W. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15682 · Cited by 126
“Additionally, GLP-1 suppresses appetite and food intake (Drucker, 2018; Shah & Vella, 2014; van Bloemendaal et al., 2014).”
BackgroundTonneijck, L., Smits, M. M., Muskiet, M. H. A., Hoekstra, T., Kramer, M. H. H., Danser, A. H. J., Diamant, M., Joles, J. A., & van Raalte, D. H. (2016) · Diabetologia · doi:10.1007/s00125-016-3938-z · Cited by 126
Self-citationGLP-1 based therapeutics: simultaneously combating T2DM and obesity
Heppner, K. M., & Perez-Tilve, D. (2015) · Frontiers in Neuroscience · doi:10.3389/fnins.2015.00092 · Cited by 115
“To further support a role for GLP-1R signaling in regulating food reward, recent fMRI studies in obese and obese T2DM patients have demonstrated that intravenous infusion of exenatide decreases the activation of brain regions involved in mediating food reward (van Bloemendaal et al., 2014).”
ResultGoldstone, A. P., Miras, A. D., Scholtz, S., Jackson, S., Neff, K. J., Pénicaud, L., Geoghegan, J., Chhina, N., Durighel, G., Bell, J. D., et al. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-2665 · Cited by 121
Monteiro, M. P., & Batterham, R. L. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.01.053 · Cited by 105
Glucagon-Like Peptide 1 Receptor Agonists and Mental Health: A Systematic Review and Meta-Analysis
Pierret, A. C. S., Mizuno, Y., Saunders, P., Lim, E., De Giorgi, R., Howes, O. D., McCutcheon, R. A., McGowan, B., Sen Gupta, P., Smith, D., et al. (2025) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2025.0679 · Cited by 116
Aldawsari, M., Almadani, F. A., Almuhammadi, N., Algabsani, S., Alamro, Y., & Aldhwayan, M. (2023) · Diabetes, Metabolic Syndrome and Obesity · doi:10.2147/dmso.s387116 · Cited by 115
“This finding offers a novel insight into the GLP-1 analogues mechanisms in regulating the food intake and could provide understanding in how weight loss achieved after GLP-1 analogues administration.(9)”
BackgroundInfluentialten Kulve, J. S., Veltman, D. J., van Bloemendaal, L., Barkhof, F., Deacon, C. F., Holst, J. J., Konrad, R. J., Sloan, J. H., Drent, M. L., Diamant, M., et al. (2015) · Diabetologia · doi:10.1007/s00125-015-3754-x · Cited by 109
“fMRI paradigm The fMRI task has been described previously [19].”
BackgroundMethodResultSelf-citationFarr, O. M., Tsoukas, M. A., Triantafyllou, G., Dincer, F., Filippaios, A., Ko, B.-J., & Mantzoros, C. S. (2016) · Metabolism · doi:10.1016/j.metabol.2016.03.009 · Cited by 105
Reward-Induced Eating: Therapeutic Approaches to Addressing Food Cravings
Rebello, C. J., & Greenway, F. L. (2016) · Advances in Therapy · doi:10.1007/s12325-016-0414-6 · Cited by 105
“In human subjects, the GLP-1 receptor agonist exenatide reduced activation in response to food cues in brain areas involved in the regulation of reward, the effect of which was greatly attenuated by GLP-1 receptor blockade [83, 84].”
BackgroundGLP-1 and Its Analogs: Does Sex Matter?
Börchers, S., & Skibicka, K. P. (2025) · Endocrinology · doi:10.1210/endocr/bqae165 · Cited by 77
GDF15 Induces an Aversive Visceral Malaise State that Drives Anorexia and Weight Loss
Borner, T., Wald, H. S., Ghidewon, M. Y., Zhang, B., Wu, Z., De Jonghe, B. C., Breen, D., & Grill, H. J. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.107543 · Cited by 100
Sex and estrogens alter the action of glucagon-like peptide-1 on reward
Richard, J. E., Anderberg, R. H., López-Ferreras, L., Olandersson, K., & Skibicka, K. P. (2016) · Biology of Sex Differences · doi:10.1186/s13293-016-0059-9 · Cited by 102
ten Kulve, J. S., Veltman, D. J., van Bloemendaal, L., Barkhof, F., Drent, M. L., Diamant, M., & IJzerman, R. G. (2016) · Diabetes Care · doi:10.2337/dc15-0772 · Cited by 102
“MRI Acquisition and Analyses MRI acquisition and analyses have been described in detail previously (14).”
BackgroundMethodSelf-citationA Role for GLP-1 in Treating Hyperphagia and Obesity
Grill, H. J. (2020) · Endocrinology · doi:10.1210/endocr/bqaa093 · Cited by 101
Salvatore, T., Galiero, R., Caturano, A., Vetrano, E., Loffredo, G., Rinaldi, L., Catalini, C., Gjeloshi, K., Albanese, G., Di Martino, A., et al. (2022) · Biomedicines · doi:10.3390/biomedicines10092274 · Cited by 98
Fortin, S. M., & Roitman, M. F. (2017) · Physiology & Behavior · doi:10.1016/j.physbeh.2017.03.019 · Cited by 90
Krajnc, N., Itariu, B. K., Macher, S., Marik, W., Harreiter, J., Michl, M., Novak, K., Wöber, C., Pemp, B., & Bsteh, G. (2023) · The Journal of Headache and Pain · doi:10.1186/s10194-023-01631-z · Cited by 97
Harasta, A. E., Power, J., von Jonquières, G., Karl, T., Drucker, D. J., Housley, G. D., Schneider, M., & Klugmann, M. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2015.47 · Cited by 97
“The preclinical potential of GLP-1 based compounds for the treatment of dependence has been broadly appreciated (Skibicka, 2013), and the translational relevance of this research is emerging (van Bloemendaal et al, 2014).”
BackgroundRoth, C. (2015) · Journal of Clinical Medicine · doi:10.3390/jcm4091774 · Cited by 89
“By binding to these receptors, GLP-1 functions as a satiety hormone, promoting reduced food intake and meal termination [153–156], as well as modulating activity in appetite- and reward-related brain areas [157].”
BackgroundSilver, H. J., Olson, D., Mayfield, D., Wright, P., Nian, H., Mashayekhi, M., Koethe, J. R., Niswender, K. D., Luther, J. M., & Brown, N. J. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15113 · Cited by 94
Martin, C. K., Carmichael, O. T., Carnell, S., Considine, R. V., Kareken, D. A., Dydak, U., Mattes, R. D., Scott, D., Shcherbinin, S., Nishiyama, H., et al. (2025) · Nature Medicine · doi:10.1038/s41591-025-03774-9 · Cited by 94
“…of selective glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) using self-report inventories suggest these therapies affect ingestive behaviors 6,7 , while functional magnetic resonance imaging (fMRI) studies using food cues show involvement of central nervous system (CNS) mechanisms 8–13 .”
The impact of gut microbial short-chain fatty acids on colorectal cancer development and prevention
Thulasinathan, B., Suvilesh, K. N., Maram, S., Grossmann, E. M., Ghouri, Y. A., Teixeiro, E., Chan, J., Kaifi, J. T., & Rachagani, S. (2025) · Gut Microbes · doi:10.1080/19490976.2025.2483780 · Cited by 92
“219–223 However, further research is required to verify whether PYY is produced outside the GIT.”
Glucagon-like peptide 1 in the pathophysiology and pharmacotherapy of clinical obesity
Anandhakrishnan, A., & Korbonits, M. (2016) · World Journal of Diabetes · doi:10.4239/wjd.v7.i20.572 · Cited by 82
Da Porto, A., Casarsa, V., Colussi, G., Catena, C., Cavarape, A., & Sechi, L. (2020) · Diabetes & Metabolic Syndrome: Clinical Research & Reviews · doi:10.1016/j.dsx.2020.03.009 · Cited by 80
Glucagon-like peptide 1 agonist and effects on reward behaviour: A systematic review
Badulescu, S., Tabassum, A., Le, G. H., Wong, S., Phan, L., Gill, H., Llach, C.-D., McIntyre, R. S., Rosenblat, J., & Mansur, R. (2024) · Physiology & Behavior · doi:10.1016/j.physbeh.2024.114622 · Cited by 90
“Likewise, Van Bloemendaal et al. (2014) presented images showing food vs non-food conditions and comparisons between high and low-calorie food conditions to obese, lean, and T2DM individuals under GLP-1RA pharmacological intervention conditions [41].”
BackgroundRoth, C. L., Perez, F. A., Whitlock, K. B., Elfers, C., Yanovski, J. A., Shoemaker, A. H., & Abuzzahab, M. J. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14224 · Cited by 87
Williams, K. J., & Wu, X. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.02.004 · Cited by 87
Smits, M. M., Fluitman, K. S., Herrema, H., Davids, M., Kramer, M. H. H., Groen, A. K., Belzer, C., de Vos, W. M., Cahen, D. L., Nieuwdorp, M., et al. (2021) · Diabetes & Metabolism · doi:10.1016/j.diabet.2021.101223 · Cited by 75
Guirguis, A., Chiappini, S., Papanti P, G., Vickers-Smith, R., Harris, D., Corkery, J., Arillotta, D., Floresta, G., Martinotti, G., & Schifano, F. (2024) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2024.02.003 · Cited by 65
Glucagon-Like Peptide-1 (GLP-1) in the Integration of Neural and Endocrine Responses to Stress
Diz-Chaves, Y., Herrera-Pérez, S., González-Matías, L. C., Lamas, J. A., & Mallo, F. (2020) · Nutrients · doi:10.3390/nu12113304 · Cited by 84
“Moreover, these effects are blocked by exendin 9-39 [287].”
BackgroundChao, A. M., Wadden, T. A., Walsh, O. A., Gruber, K. A., Alamuddin, N., Berkowitz, R. I., & Tronieri, J. S. (2019) · Obesity · doi:10.1002/oby.22653 · Cited by 84
Alterations in white matter volume and integrity in obesity and type 2 diabetes
van Bloemendaal, L., IJzerman, R. G., ten Kulve, J. S., Barkhof, F., Diamant, M., Veltman, D. J., & van Duinkerken, E. (2016) · Metabolic Brain Disease · doi:10.1007/s11011-016-9792-3 · Cited by 84
“Inclusion and exclusion criteria have been reported previously (van Bloemendaal et al. 2014).”
BackgroundSelf-citationDecara, J., Rivera, P., Arrabal, S., Vargas, A., Serrano, A., Pavón, F. J., Dieguez, C., Nogueiras, R., Rodríguez de Fonseca, F., & Suárez, J. (2018) · Acta Physiologica · doi:10.1111/apha.13008 · Cited by 76
“Central (1-3 nmol or 1-10 lg) or intravenous (600 pmol kg 1 min (1)) administration of GLP-1 in rodents and humans significantly suppressed food intake.(17,43,44) The reduction in energy intake involved a reduction in appetite along with an increase in satiety and a reduction in feelings of hunger.”
BackgroundChiappini, S., Vickers-Smith, R., Harris, D., Papanti Pelletier, G. D., Corkery, J. M., Guirguis, A., Martinotti, G., Sensi, S. L., & Schifano, F. (2023) · Pharmaceuticals · doi:10.3390/ph16070994 · Cited by 78
Salehi, P., Hsu, I. R., Azen, C., Mittelman, S. D., Geffner, M. E., & Jeandron, D. D. (2016) · Pediatric Obesity · doi:10.1111/ijpo.12131 · Cited by 78
Intestinal GLP-1 and satiation: from man to rodents and back
Steinert, R. E., Beglinger, C., & Langhans, W. (2015) · International Journal of Obesity · doi:10.1038/ijo.2015.172 · Cited by 78
Lakerveld, J., Palmeira, A. L., van Duinkerken, E., Whitelock, V., Peyrot, M. F., & Nouwen, A. (2020) · Diabetic Medicine · doi:10.1111/dme.14228 · Cited by 77
Angarita, G. A., Matuskey, D., Pittman, B., Costeines, J. L., Potenza, M. N., Jastreboff, A. M., Schmidt, H. D., & Malison, R. T. (2021) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2021.108614 · Cited by 75
van Bloemendaal, L., Veltman, D. J., ten Kulve, J. S., Drent, M. L., Barkhof, F., Diamant, M., & IJzerman, R. G. (2015) · Obesity · doi:10.1002/oby.21200 · Cited by 67
Self-citationMansur, R. B., Zugman, A., Ahmed, J., Cha, D. S., Subramaniapillai, M., Lee, Y. L., Lovshin, J. A., Lee, J. G., Lee, J.-H., Drobinin, V., et al. (2017) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2017.08.433 · Cited by 73
Clinical pharmacology of glucagon-like peptide-1 receptor agonists
Sfairopoulos, D. G., Liatis, S., Tigas, S. K., & Liberopoulos, E. N. (2018) · HORMONES · doi:10.1007/s42000-018-0038-0 · Cited by 73
Bornebusch, A. B., Fink-Jensen, A., Wörtwein, G., Seeley, R. J., & Thomsen, M. (2019) · eneuro · doi:10.1523/eneuro.0443-18.2019 · Cited by 72
“GLP-1 receptors are expressed in peripheral tissues like the pancreas, and in many brain regions, and GLP-1 regulates feeding behavior and food intake at least in part through central mechanisms (Skibicka, 2013; Sisley et al., 2014; van Bloemendaal et al., 2014).”
BackgroundGLP-1 signaling and alcohol-mediated behaviors; preclinical and clinical evidence
Jerlhag, E. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.01.013 · Cited by 72
Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) in the Brain–Adipocyte Axis
Geloneze, B., de Lima-Júnior, J. C., & Velloso, L. A. (2017) · Drugs · doi:10.1007/s40265-017-0706-4 · Cited by 60
Endogenous GLP1 and GLP1 analogue alter CNS responses to palatable food consumption
ten Kulve, J. S., Veltman, D. J., van Bloemendaal, L., Groot, P. F. C., Ruhé, H. G., Barkhof, F., Diamant, M., & Ijzerman, R. G. (2016) · Journal of Endocrinology · doi:10.1530/joe-15-0461 · Cited by 66
“MRI acquisition methods have been described previously (van Bloemendaal et al. 2014).”
MethodSelf-citationvan Raalte, D. H., & Verchere, C. B. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12935 · Cited by 69
“In addition, reduced appetite limits the size of the ingested meal.(85) All these factors result in reduced postprandial glucose, and thus insulin levels.”
BackgroundGIP and GLP-1 receptor antagonism during a meal in healthy individuals
Gasbjerg, L. S., Helsted, M. M., Hartmann, B., Sparre-Ulrich, A. H., Veedfald, S., Stensen, S., Lanng, A. R., Bergmann, N. C., Christensen, M. B., Vilsbøll, T., et al. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgz175 · Cited by 68
Bettadapura, S., Dowling, K., Jablon, K., Al-Humadi, A. W., & le Roux, C. W. (2025) · International Journal of Obesity · doi:10.1038/s41366-024-01500-y · Cited by 55
“Patients who used the GLP-1 receptor agonist exenatide displayed decreased neuronal responses to pictures of food measured by functional magnetic resonance imaging (fMRI) in parts of the brain that relate to appetite and reward (insula, amygdala, putamen, and orbitofrontal cortex) [36].”
Le, R., Nguyen, M. T., Allahwala, M. A., Psaltis, J. P., Marathe, C. S., Marathe, J. A., & Psaltis, P. J. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13164674 · Cited by 66
“There is also evidence that GLP-1 RAs can attenuate hyperstimulation of neural appetite and reward centres (insula, amygdala, putamen and orbitofrontal cortex) through direct GLP-1R agonism [38].”
BackgroundA phase 1 multiple‐ascending dose study of tirzepatide in Japanese participants with type 2 diabetes
Furihata, K., Mimura, H., Urva, S., Oura, T., Ohwaki, K., & Imaoka, T. (2022) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14572 · Cited by 59
Huang, S., Ma, S.-Y., Ning, M., Yang, W., Ye, Y., Zhang, L., Shen, J., & Leng, Y. (2019) · Metabolism · doi:10.1016/j.metabol.2019.07.003 · Cited by 65
Glucagon-like peptide-1 receptor agonists and muscle mass effects
Ceasovschih, A., Asaftei, A., Lupo, M. G., Kotlyarov, S., Bartušková, H., Balta, A., Sorodoc, V., Sorodoc, L., & Banach, M. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107927 · Cited by 64
Bak, M., Campforts, B. C. M., Domen, P. A. E., van Amelsvoort, T., & Drukker, M. (2024) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.13734 · Cited by 64
Guerrero-Hreins, E., Goldstone, A. P., Brown, R. M., & Sumithran, P. (2021) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2021.110303 · Cited by 62
Metadata
- Authors
- van Bloemendaal, L., IJzerman, R. G., ten Kulve, J. S., Barkhof, F., Konrad, R. J., Drent, M. L., Veltman, D. J., & Diamant, M.
- Affiliations
- Diabetes Center, Department of Internal Medicine, VU University Medical Center, Amsterdam, the Netherlands
- Amsterdam UMC Location Vrije Universiteit Amsterdam (NL)
- Eli Lilly (United States) (US)
- Amsterdam Neuroscience (NL)
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2014-11-13
- Volume
- 63
- Issue
- 12
- Pages
- 4186-4196
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- OpenAlex
- W2018940614
- Cited by
- 427
- References
- 56
- Citations by year
- 2026: 52 · 2025: 60 · 2024: 44 · 2023: 39 · 2022: 25 · 2021: 35 · 2020: 28 · 2019: 25 · 2018: 22 · 2017: 30 · 2016: 34 · 2015: 29 · 2014: 4
- FWCI
- 15.76
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes (publishedVersion)
- PubMed (publishedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Pure Amsterdam UMC (submittedVersion)
- VU Research Portal (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Topics
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Keywords
- GLP-1 receptor agonists, exenatide, exendin-9-39, appetite regulation, food reward, food images, obesity, type 2 diabetes, satiety, insula, amygdala, orbitofrontal cortex, putamen, weight loss
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Exenatide, Adult, Aged, Amygdala, Appetite, Brain, Cerebral Cortex, Diabetes Mellitus, Type 2, Feeding Behavior, Female, Humans, Hypoglycemic Agents, Magnetic Resonance Imaging, Male, Middle Aged, Obesity, Peptide Fragments, Peptides, Photic Stimulation, Putamen, Reward, Venoms, Case-Control Studies, Prefrontal Cortex, Receptors, Glucagon, Cross-Over Studies, Functional Neuroimaging
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.